Latest News and Press Releases
Want to stay updated on the latest news?
-
LIfT BioSciences heralds a new era of affordable effective cancer cell therapies simply produced from iPSCs LIfT announces successful production of first-in-class neutrophil based cell therapy from...
-
- IMAN demonstrated potent direct killing of a patient derived pancreatic ductal adenocarcinoma tumouroid model - IMAN is the world’s first neutrophil-based cell therapy, generated...
-
- IMAN demonstrated potent direct killing of a patient derived pancreatic ductal adenocarcinoma tumouroid model - IMAN is the world’s first neutrophil-based cell therapy, generated...
-
LIfT BioSciences announces breakthrough preclinical data demonstrating the dual mode of action commonly believed necessary for curing solid tumours IMANp is the world’s first neutrophil-based cell...
-
LIfT BioSciences announces breakthrough preclinical data demonstrating the dual mode of action commonly believed necessary for curing solid tumours IMANp is the world’s first neutrophil-based cell...
-
LIfT BioSciences investors increase investment in LIfT and Johnson and Johnson welcomes LIfT into JLABS Additional investment supports plans for N-LIfT to enter the clinic by Q1 2024 London, 19...
-
LIfT BioSciences investors increase investment in LIfT and Johnson and Johnson welcomes LIfT into JLABS Additional investment supports plans for N-LIfT to enter the clinic by Q1 2024 London, 19...
-
LIfT BioSciences announces its N-LIfT cell therapy shows tumour destruction across five different solid tumour types in PDX tumouroid models London, 14th September 2022 – LIfT BioSciences today...
-
LIfT BioSciences announces its N-LIfT cell therapy shows tumour destruction across five different solid tumour types in PDX tumouroid models London, 14th September 2022 – LIfT BioSciences today...
-
LIfT BioSciences N-LIfT cell therapy shows complete and superior cell killing in solid tumour organoids compared to Keytruda Research reinforces the value of using Tumouroid models as efficacy...